INmune Bio (INMB) announced that a video detailing the additional findings from the Phase 2 MINDFuL trial evaluating XPro, a novel selective soluble TNF inhibitor, will be published on the company’s YouTube Channel following the conclusion of Alzheimer’s Association International Conference, AAIC, in Toronto, Canada. This forthcoming video will offer an overview of the latest clinical insights shared during the Alzheimer’s Association International Conference. Viewers can expect an in-depth exploration of how XPro was evaluated within the MINDFuL study design, as well as the significance of the findings for patients, clinicians, and investors interested in the evolving landscape of Alzheimer’s disease therapies.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INMB:
- Inmune Bio Reveals Promising XPro™ Trial Results
- INmune Bio announces analyses from Phase 2 MINDFuL trial, endpoint not met
- Largest borrow rate increases among liquid names
- INmune Bio price target lowered to $7 from $20 at Alliance Global Partners
- INmune Bio price target lowered to $8 from $30 at Maxim